Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.
- Jaffrain-Rea, Marie-Lise
- Angelini, M.
- Gargano, D.
- Tichomirowa, M. A.
- Daly, Adrian
- Vanbellinghen, Jean-François
- D'Innocenzo, E.
- Barlier, Anne
- Giangaspero, F.
- Esposito, Vincenzina
- Ventura, L.
- Arcella, A.
- Theodoropoulou, M.
- Naves, Luciana Ansaneli
- Fajardo, C.
- Zacharieva, S.
- Rohmer, V.
- Brue, T.
- Gulino, A.
- Cantore, G.
- Alesse, E.
- Beckers, Albert
DOIAbstract
Germline mutations of the aryl hydrocarbon receptor (AHR)-interacting protein (AIP) gene confer a predisposition to pituitary adenomas (PA), usually in the setting of familial isolated PA. To provide further insights into the possible role of AIP in pituitary tumour pathogenesis, the expression of AIP and AHR was determined by real-time RT-PCR and/or immunohistochemistry (IHC) in a large series of PA (n=103), including 17 with AIP mutations (AIP(mut)). Variable levels of AIP and AHR transcripts were detected in all PA, with a low AHR expression (P<0.0001 versus AIP). Cytoplasmic AIP and AHR were detected by IHC in 84.0 and 38.6% of PA respectively, and significantly correlated with each other (P=0.006). Nuclear AHR was detected in a minorit...
Add to ORKG